What are the different policies for the sale of drugs in hospitals between those who have won the bid and those who have not?

Supplementary regulations on the natural replacement of unsuccessful drugs with successful ones In order to standardize the management of drugs in our hospital, strictly implement the centralized bidding and purchasing policy for drugs at the provincial level, and to use successful drugs to ensure that patients in the hospital have access to medication, we have formulated these supplementary regulations in accordance with the spirit of the "Regulations on the Natural Replacement of Unsuccessful Drugs with Successful Drugs", which was adopted by the Third Pharmaceutical Committee in 2007, and in the light of new requirements and development of the management of drugs in the new form. In accordance with the spirit of the Regulations on the Management of Natural Replacement of Unsuccessful Drugs with Winning Drugs adopted at the third meeting of the Medicines Committee in 2007, and taking into account the new requirements and developments in the management of medicines in the new form, the present supplementary regulations are formulated. 1. It is required that the products to be replaced must be in use in our hospitals, and that the products to be replaced have legal distribution companies and authorized sales consignors in our hospitals. 2. 2. The replacement varieties must be therapeutic drugs or varieties and specifications that are clinically needed in the hospital, and the unsuccessful varieties will not be replaced if they are not suitable for the clinical specifications or if the replacement can also satisfy the needs of the clinical use of drugs. 3. 3. Replacement of unsuccessful varieties shall be requested by the applicant for replacement, and the application for replacement shall be submitted to the Department of Pharmacy within a specified period of time for centralized discussion and report to the hospital's Pharmacy Committee. 4. 4. In general, the replacement varieties must have the same generic name as the original varieties (except for the case of regulation 11), and shall not change the route of medication. 5. 5. In principle, replacement varieties should have brand name advantages and appropriate drug prices. 6. 6. In general, the natural replacement varieties are preferred to be replaced by the authorized sales commissioner of the replaced varieties in the hospital, but he/she must obtain the authorized sales commission of the replaced varieties in the hospital. If the clinical department has already submitted a new drug application to the pharmacy department before applying for a replacement variety, and the new drug application is of the same approval number as the variety to be replaced, and if the applicant for the replacement variety has not obtained the authorization of the sales entrustment of the new drug application, the application for the new drug application of the clinical department is valid but cannot be replaced naturally. If the clinical department has already submitted a new drug application to the pharmacy department before applying for a replacement variety, but it does not belong to the same approval number as the variety applied for replacement, the applicant for replacement will be deferred from obtaining the access qualification of the replacement variety applied for in the hospital; if the person who applies for the replacement has not obtained the authorization of sales commission for the drug of the approval number or belongs to the situation that the hospital explicitly does not allow the replacement, the application for a new drug of the clinical department is valid, and the hospital's pharmacy committee discusses whether to introduce it or not. 7. When there is a conflict of authorization for sale of the same replacement product, the original authorized seller of the product to be replaced shall be given priority. 8. The applicant for replacement must be the original authorized seller of the unsuccessful variety. 9. 9. The unsuccessful varieties must be returned to the original supplier company at the agreed or specified time. 10. 10. The following cases do not belong to the scope of natural replacement: 1) Changing the generic name of the drug, and the main drug ingredients have changed, and the drug action category, nature, and the main adverse reactions have changed. 2) The varieties have the same generic name, but the varieties are not the same. 2) Species with the same common name, but the route of use has changed and the bioavailability is different. 3) Varieties that do not have the qualification to apply for the replacement of the replacement application. 4) The supplier changes the client privately, and there is trading of varieties. 11. 11. Natural replacement can be considered in the following cases: 1) PCMs with the same class of drugs, the same main effects, and only individual ingredient changes in the formula. 2) Pentacosan medicines with the same main effects, and only individual ingredient changes in the formula. 2) Pentacosanal medicines with the same main ingredients, only the excipients are different. Yueyang First Hospital Pharmacy Committee